INTERVIEW WITH NOEL CLARKE
Treating the Primary in High vs Low Volume Hormone Sensitive Disease

INTERVIEW WITH DECLAN MURPHY
Imaging Modalities to Treat Node-Positive Disease

INTERVIEW WITH FRED SAAD
The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer

INTERVIEW WITH COLIN PRITCHARD
Integrating Genomics and Genetics into Clinical Care for Prostate Cancer, A Pathologist's Perspective

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

Current Strategies in the Management of Peyronie's Disease (PD)-Results of a Survey of 401 Sexual Medicine Experts Across Europe.

Peyronie's disease (PD) is a progressive and devastating penile disorder that often results in severe penile curvature with penile shrinking, making vaginal insertion difficult or even impossible. Until now, in contrast to other penile disorders such as erectile dysfunction, PD is characterized by a paucity of conservative treatment options.

To investigate the current status quo in the management of PD across European experts in sexual medicine.

Members of the European Society of Sexual Medicine and of various andrology and urology societies across Europe, with the majority (78%) being urologists, were contacted via e-mail and newsletters and asked to fill in an online questionnaire. The survey comprised 56 items developed by an expert consensus of the educational committee of the European Society of Sexual Medicine. In the end, 401 participants responded to the entire survey, with 277 reporting treating PD patients themselves and knowing this penile entity very well.

Main outcome measures include description of current strategies regarding diagnosis and treatment of PD as reported by specialists in this field.

Of the physicians treating PD patients, 94% performed penile palpation, and 74% perform ultrasonography. 45% assessed the degree of penile curvature by means of intravenous drug testing, but only 17% measured it accurately with a goniometer. Penile length, flaccid or in erect state, was measured by only 39% or 25%, respectively. Only 45% assessed testosterone. Primary treatment options were oral (65%), counseling (57%), and topical/local therapy (30%). Among oral drug users, tadalafil 5 mg was the most commonly used (57%), followed by vitamin E (40%). Regarding intralesional therapy, collagenase clostridium histolyticum was the leading drug (34%), followed by calcium channel blockers (17%). Considering surgical procedures, the original Nesbit technique was the preferred procedure (33%). 36% of the specialists expressed their dissatisfaction with the currently available treatment options, and 64% reported the impression that their patients were mostly dissatisfied with the treatment outcomes.

Innovative and presumably multi-modal treatment protocols for PD are urgently needed.

The survey represents 1 of the largest studies on the management of PD. The results are representative for the standard management of PD mostly among European Urologists with specialization in sexual medicine and may therefore not be generalizable to regions outside Europe or to other physicians treating PD.

Around one-third of experts and, from their perspective, around two-thirds of patients are dissatisfied with the currently available PD treatment options. Porst H, Burri A, the European Society for Sexual Medicine (ESSM) Educational Committee. Current Strategies in the Management of Peyronie's Disease (PD)-Results of a Survey of 401 Sexual Medicine Experts Across Europe. J Sex Med 2019;XX:XXX-XXX.

The journal of sexual medicine. 2019 May 15 [Epub ahead of print]

Hartmut Porst, Andrea Burri, European Society for Sexual Medicine (ESSM) Educational Committee

European Institute for Sexual Health (EISH), Hamburg, Germany. Electronic address: ., European Institute for Sexual Health (EISH), Hamburg, Germany.

Conference Coverage
 
Recent data from conferences worldwide
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
  • 2019 World Congress / May 1-3 / Liverpool, United Kingdom
  • 2019 Symposium / April 1-4 / Ottawa, ON
Journals
Publications focusing on urologic cancer treatments through original manuscripts
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe